Abstract: A panty construction features a rear panel formed of a dyable exposed LYCRA material. Side seams join the rear panel to a front panel that is formed of a non-exposed elastomer material. The side seams are positioned medial of the anterior superior iliac spine. Bar tack stitches are used at the top and at the bottom of the side seams as well as the forward lateral edges of a gusset. The gusset is positioned solely on the front panel.

Abstract: A process for the preparation of C4 to C24 alkyl polyglycosides by the use of an enzyme to react C4 to C24 alkyl glycoside with a glycosyl donor containing monosaccharide residues, wherein the C4 to C24 alkyl polyglycosides have a mole-average degree of polymerization (mean DP) of the glycoside chains of greater than 1.5 units. The C4 to C24 alkyl polyglycosides are particularly useful in personal care formulations.

Abstract: An enzymatic process for the preparation of C16 alkyl polyglycosides and/or C18 alkyl polyglycosides by reacting C16 alkyl glycoside and/or C18 alkyl glycoside with a glycosyl donor containing monosaccharide residues to form an alkyl polyglycoside intermediate which can be fractionated to form an alkyl polyglycoside product, wherein the mole-average degree of polymerization mean DP) of the glycoside chains is greater than or equal to 3.0 units and the molar concentration of alkyl triglycoside (DP3) is greater than alkyl monoglycoside (DPI). The C16/C18 alkyl polyglycoside product is particularly useful in health care formulations, especially in combination with and/or as a solubilizer for active pharmaceutical ingredients (APIs).

Abstract: A panty construction features a rear panel formed of a dyable exposed LYCRA material. Side seams join the rear panel to a front panel that is formed of a non-exposed elastomer material. The side seams are positioned medial of the anterior superior iliac spine. Bar tack stitches are used at the top and at the bottom of the side seams as well as the forward lateral edges of a gusset. The gusset is positioned solely on the front panel.

Abstract: The invention describes antagonists for PDGF. The antagonists contain amino acids, and may be monomers or dimers. Especially preferred are dimers which bind the PDGF receptors, but prevent dimerization of the bound receptors. Dimerization is necessary for PDGF effect, hence the antagonistic effect. Also described are nucleic acid sequences for making the antagonists, as well as cell lines transfected with the material.

Abstract: The invention described PDGF modifiers. These are peptides which are derived from wild type PDGF monomers, and function as either agonists or antagonists. Various uses of these are described, as well as recombinant means of production. PDGF-B agonists comprising amino acids 97-180 of the PDGF-B monomer having the cysteines at amino acid residues 124 and 133 substituted, nucleic acid molecules encoding the agonists, plasmids, transformed host cells, and methods for causing receptor dimerization and autophosphorylation in a cell having PDGF-.beta. receptors on its surface comprising administering the PDGF-B agonist form part of the invention.